Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: A meta-analysis

Respirology

Volumn 20, Issue 1, 2015, Pages 56-65

  Wang, Huoqiang ^a   Wu, Songnian ^b   Zhao, Long ^a   Zhao, Juan ^a   Liu, Jinjun ^a   Wang, Zhihao ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Radiopharmaceutical Lab   (China)

Author keywords

diagnostic; meta analysis; microRNA; non small cell lung cancer

Indexed keywords

MICRORNA; TUMOR MARKER;

AREA UNDER THE CURVE; ASIAN; CANCER DIAGNOSIS; CANCER PATIENT; CAUCASIAN; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; REVIEW; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LUNG NEOPLASMS; MICRORNAS; SENSITIVITY AND SPECIFICITY;

EID: 84918573733     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12444     Document Type: Review

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J. Clin. 2014; 64: 9-29.
2. Al-Saleh K, Quinton C, Ellis PM,. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr. Oncol. 2012; 19: e9-15.
3. Indovina P, Marcelli E, Maranta P, Tarro G,. Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics 2011; 2011: 726869.
4. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS,. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006; 355: 1763-1771.
5. Sanfiorenzo C, Ilie MI, Belaid A, Barlesi F, Mouroux J, Marquette CH, Brest P, Hofman P,. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE 2013; 8: e54596.
6. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, Ascher S, Bailey W, Brewer B, Church T, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005; 47: 9-15.
7. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD,. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011; 365: 395-409.
8. Vansteenkiste J, Dooms C, De Leyn P,. Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging. Ann. Oncol. 2010; 21 (Suppl. 7): vii189-195.
9. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E, Califano JA,. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 2012; 7: e32307.
10. Shen Y, Wang T, Yang T, Hu Q, Wan C, Chen L, Wen F,. Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis. Genet. Test. Mol. Biomarkers 2013; 17: 359-366.
11. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, Guerrero JM,. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clin. Lab. 2011; 57: 1011-1014.
12. Pritchard CC, Cheng HH, Tewari M,. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 2012; 13: 358-369.
13. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 2011; 91: 579-587.
14. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S,. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 2012; 130: 1620-1628.
15. Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, Gazala S, Ghosh S, Wong E, Joy AA, et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin. Invest. Med. 2012; 35: E271.
16. Huang Y, Hu Q, Deng Z, Hang Y, Wang J, Wang K,. MicroRNAs in body fluids as biomarkers for non-small cell lung cancer: a systematic review. Technol. Cancer Res. Treat. 2014; 13: 277-287.
17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM,. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011; 155: 529-536.
18. Jackson D, White IR, Thompson SG,. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. Stat. Med. 2010; 29: 1282-1297.
19. Deeks JJ, Macaskill P, Irwig L,. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 2005; 58: 882-893.
20. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, Jiang F,. Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis. J. Thorac. Oncol. 2014; 9: 33-40.
21. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F,. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J. Cancer Res. Clin. Oncol. 2014; 140: 145-150.
22. Gao F, Chang J, Wang H, Zhang G,. Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol. Rep. 2014; 31: 351-357.
23. Zeng XL, Zhang SY, Zheng JF, Yuan H, Wang Y,. Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin. Med. J. 2013; 126: 4510-4516.
24. Yang XQ, Zhang YH, Sun P, Deng P, Fan J, Shen JH, Zhu GY, Gu MF,. Diagnostic value of the detection of microRNAs in sputum of patients with non-small cell lung caner. J. Clin. Pulm. Med. 2013; 18: 226-229.
25. Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W,. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int. J. Mole. Sci. 2013; 14: 10332-10342.
26. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y,. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur. J. Cancer Prev. 2013; 22: 540-548.
27. Mozzoni P, Banda I, Goldoni M, Corradi M, Tiseo M, Acampa O, Balestra V, Ampollini L, Casalini A, Carbognani P, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers 2013; 18: 679-686.
28. Ma J, Li N, Guarnera M, Jiang F,. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomarker Insights 2013; 8: 127-136.
29. Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI,. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. 2013; 8: 1156-1162.
30. Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML,. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem. Biophys. 2013; 67: 875-884.
31. Zhao M, Shen XK, Zhan P, Lv TF, Liu HB, Song Y,. Expression of miRNA-29a in non-small cell lung cancer and clinical significance. Chin. Clin. Oncol. 2012; 17: 428-432.
32. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A,. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS ONE 2012; 7: e46045.
33. Ma Y, Tian Z, Zhang W,. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J. Cancer Res. Clin. Oncol. 2012; 138: 2045-2050.
34. Li GJ, Huang YC, He YF, Chen JB, Yang KY, Zhao GQ, Lei YJ, Chen Y,. Study of miRNA signatures as biomarkers for early stage nonsmoking female lung cancer of Xuanwei county of Yunan Province. Cancer Res. Prev. Treat. 2012; 39: 802-806.
35. Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, Shu YQ,. Reduction of plasma microRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin. J. Cancer Res. 2011; 23: 123-128.
36. Liu S, Yang JY,. Application of plasma circulation microRNA-126 to diagnosis of non-small cell lung cancer. Med. J. Natl. Defending Forces Southwest China 2011; 21: 1280-1283.
37. Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK,. Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol. Med. Reports 2011; 4: 383-387.
38. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ,. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 2011; 6: 482-488.
39. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP,. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 2011; 3: 495-503.
40. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F,. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010; 127: 2870-2878.
41. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F,. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010; 67: 170-176.
42. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E,. miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009; 9: 353.